Phospholipids of the lung in normal, toxic, and diseased states.
The highly pulmonary concentration of 1,2-dipalmitoyl-sn-glycerol-3-phosphorylcholine (dipalmitoyllecithin) and its implication as an important component of lung surfactant have promoted investigation of phospholipid metabolism in the lung. This review will set the contents including recent informations for better understanding of phospholipid metabolism of the lung in normal state (physiological significances of lung phospholipids, characteristics of phospholipids in lung tissue and alveolar washing, biosynthetic pathways of dipalmitoyllecithin, etc.) as well as in toxic states (pulmonary oxygen toxicity, etc.) and in diseased states (idiopathic respiratory distress syndrome, pulmonary alveolar proteinosis, etc.) Since our main concern has been to clarify the most important route for supplying dipalmitoyllecithin, this review will be focused upon the various biosynthetic pathways leading to the formation of different molecular species of lecithin and their potential significance in the normal, toxic, and diseased lungs.
D005333:Fetus / Q000378:metabolism / Q000502:physiology; D006801:Humans; D008168:Lung / Q000196:embryology / Q000378:metabolism / Q000502:physiology* / Q000503:physiopathology; D008171:Lung Diseases / Q000139:chemically induced / Q000503:physiopathology*; D009585:Nitrogen Dioxide / Q000009:adverse effects; D010100:Oxygen / Q000009:adverse effects; D010126:Ozone / Q000009:adverse effects; D010713:Phosphatidylcholines / Q000096:biosynthesis / Q000378:metabolism; D010743:Phospholipids / Q000378:metabolism / Q000502:physiology*; D011649:Pulmonary Alveolar Proteinosis / Q000503:physiopathology; D011663:Pulmonary Surfactants / Q000096:biosynthesis / Q000502:physiology; D012128:Respiratory Distress Syndrome / Q000503:physiopathology
D010713:Phosphatidylcholines; D010743:Phospholipids; D011663:Pulmonary Surfactants; D010126:Ozone; D009585:Nitrogen Dioxide; D010100:Oxygen